PROM2 and familial pancreatic carcinoma: Statistical analysis confirmed that the expression of PROM2 was significantly correlated with clinical stages in patients with pancreatic cancer, and also indicated lower overall survival and disease-free survival rates (Supplementary Tables S1–S2).